310 related articles for article (PubMed ID: 23509102)
1. Mitochondria-targeted nitroxide, Mito-CP, suppresses medullary thyroid carcinoma cell survival in vitro and in vivo.
Starenki D; Park JI
J Clin Endocrinol Metab; 2013 Apr; 98(4):1529-40. PubMed ID: 23509102
[TBL] [Abstract][Full Text] [Related]
2. Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells.
Starenki D; Hong SK; Wu PK; Park JI
Cancer Biol Ther; 2017 Jul; 18(7):473-483. PubMed ID: 28475408
[TBL] [Abstract][Full Text] [Related]
3. Recombinant leukemia inhibitory factor suppresses human medullary thyroid carcinoma cell line xenografts in mice.
Starenki D; Singh NK; Jensen DR; Peterson FC; Park JI
Cancer Lett; 2013 Oct; 339(1):144-51. PubMed ID: 23856028
[TBL] [Abstract][Full Text] [Related]
4. YAP confers resistance to vandetanib in medullary thyroid cancer.
Wang H; Tang J; Su Z
Biochem Cell Biol; 2020 Jun; 98(3):443-448. PubMed ID: 32449862
[TBL] [Abstract][Full Text] [Related]
5. Mortalin (GRP75/HSPA9) upregulation promotes survival and proliferation of medullary thyroid carcinoma cells.
Starenki D; Hong SK; Lloyd RV; Park JI
Oncogene; 2015 Aug; 34(35):4624-34. PubMed ID: 25435367
[TBL] [Abstract][Full Text] [Related]
6. Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model.
Carra S; Gaudenzi G; Dicitore A; Saronni D; Cantone MC; Plebani A; Ghilardi A; Borghi MO; Hofland LJ; Persani L; Vitale G
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809722
[TBL] [Abstract][Full Text] [Related]
7. Vandetanib therapy in medullary thyroid cancer.
Grabowski P; Briest F; Baum RP; Zaknun JJ; Kulkarni HR; Zeitz M; Hörsch D
Drugs Today (Barc); 2012 Nov; 48(11):723-33. PubMed ID: 23170308
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer.
Del Rivero J; Edgerly M; Ward J; Madan RA; Balasubramaniam S; Fojo T; Gramza AW
Oncologist; 2019 Jan; 24(1):16-e14. PubMed ID: 30297385
[TBL] [Abstract][Full Text] [Related]
9. A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis.
Johanson V; Ahlman H; Bernhardt P; Jansson S; Kölby L; Persson F; Stenman G; Swärd C; Wängberg B; Stridsberg M; Nilsson O
Endocr Relat Cancer; 2007 Jun; 14(2):433-44. PubMed ID: 17639056
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional targeting of oncogene addiction in medullary thyroid cancer.
Valenciaga A; Saji M; Yu L; Zhang X; Bumrah C; Yilmaz AS; Knippler CM; Miles W; Giordano TJ; Cote GJ; Ringel MD
JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135308
[TBL] [Abstract][Full Text] [Related]
11. Changes in signaling pathways induced by vandetanib in a human medullary thyroid carcinoma model, as analyzed by reverse phase protein array.
Broutin S; Commo F; De Koning L; Marty-Prouvost B; Lacroix L; Talbot M; Caillou B; Dubois T; Ryan AJ; Dupuy C; Schlumberger M; Bidart JM
Thyroid; 2014 Jan; 24(1):43-51. PubMed ID: 24256343
[TBL] [Abstract][Full Text] [Related]
12. Vandetanib and the management of advanced medullary thyroid cancer.
Campbell MJ; Seib CD; Gosnell J
Curr Opin Oncol; 2013 Jan; 25(1):39-43. PubMed ID: 23202050
[TBL] [Abstract][Full Text] [Related]
13. Systemic treatment and management approaches for medullary thyroid cancer.
Ernani V; Kumar M; Chen AY; Owonikoko TK
Cancer Treat Rev; 2016 Nov; 50():89-98. PubMed ID: 27664392
[TBL] [Abstract][Full Text] [Related]
14. Mortalin (GRP75/HSPA9) Promotes Survival and Proliferation of Thyroid Carcinoma Cells.
Starenki D; Sosonkina N; Hong SK; Lloyd RV; Park JI
Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31027376
[TBL] [Abstract][Full Text] [Related]
15. Suppression of B-Raf
Hong SK; Starenki D; Wu PK; Park JI
Cancer Biol Ther; 2017 Feb; 18(2):106-114. PubMed ID: 27786591
[TBL] [Abstract][Full Text] [Related]
16. Selective Mitochondrial Uptake of MKT-077 Can Suppress Medullary Thyroid Carcinoma Cell Survival In Vitro and In Vivo.
Starenki D; Park JI
Endocrinol Metab (Seoul); 2015 Dec; 30(4):593-603. PubMed ID: 26485469
[TBL] [Abstract][Full Text] [Related]
17. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
[No Abstract] [Full Text] [Related]
18. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.
Bentzien F; Zuzow M; Heald N; Gibson A; Shi Y; Goon L; Yu P; Engst S; Zhang W; Huang D; Zhao L; Vysotskaia V; Chu F; Bautista R; Cancilla B; Lamb P; Joly AH; Yakes FM
Thyroid; 2013 Dec; 23(12):1569-77. PubMed ID: 23705946
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor activity of motesanib in a medullary thyroid cancer model.
Coxon A; Bready J; Kaufman S; Estrada J; Osgood T; Canon J; Wang L; Radinsky R; Kendall R; Hughes P; Polverino A
J Endocrinol Invest; 2012 Feb; 35(2):181-90. PubMed ID: 21422803
[TBL] [Abstract][Full Text] [Related]
20. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.
Vitagliano D; De Falco V; Tamburrino A; Coluzzi S; Troncone G; Chiappetta G; Ciardiello F; Tortora G; Fagin JA; Ryan AJ; Carlomagno F; Santoro M
Endocr Relat Cancer; 2011 Feb; 18(1):1-11. PubMed ID: 20943719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
